NCT04294641 2026-01-23Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host DiseaseNational Institutes of Health Clinical Center (CC)Phase 2 Completed10 enrolled 15 charts
NCT04063215 2026-01-15A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic EncephalopathyHope Biosciences Research FoundationPhase 1/2 Completed24 enrolled 67 charts
NCT03790332 2025-10-21Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)Pharmacyclics LLC.Phase 1/2 Completed59 enrolled 2 FDA
NCT03112603 2025-08-12A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)Incyte CorporationPhase 3 Completed330 enrolled 32 charts 2 FDA